Beginning operations in late 2020, Andelyn Biosciences will become a Phase 3 compliant Good Manufacturing Practices (cGMP) clinical manufacturing facility producing materials for phase 1, 2, and 3 gene therapy clinical studies for biotechnology and pharmaceutical industries around the world.
Andelyn Biosciences is driven by its purpose, its reliable quality and its expertise. In short, the company is a game-changer. Unique scientific and manufacturing capabilities are paired with life-changing research. Therapies for incurable diseases and rare disorders are the result.
Andelyn Biosciences’ unique business model leads to reinvestment into pioneering research conducted at the Abigail Wexner Research Institute at Nationwide Children's, from basic discovery science to population health research on a broad range of challenges affecting children’s health.